Full Press Release Details
Titan Pharmaceuticals Receives Funding to Develop
Combination HIV Therapeutic and Contraceptive Implant for Women in Developing Countries
SOUTH SAN FRANCISCO, CA - October 25, 2021
- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today announced that it has received
funding from the Bill & Melinda Gates Foundation to support the demonstration of its ability to deliver a human immunodeficiency virus
("HIV") preventative therapeutic and a contraceptive from a single implant using its proprietary ProNeura
technology, and ensure this technology is accessible to women and adolescent girls in low- and middle-income countries.
"Reducing the burden of HIV, while simultaneously
increasing access to contraceptive options, could have a major impact on the health of women and adolescent girls in low- and middle-income
countries," said Marc Rubin, M.D., Executive Chairman of Titan. "We believe that our ProNeura platform is uniquely suited
to this program, as we have demonstrated the feasibility of long-term delivery of two pharmaceutically active ingredients from a single
implant in an earlier development program. The continuous long-term delivery of a contraceptive/antiviral combination has the potential
to have a greater public health impact in developing nations, compared with daily dosing of multiple compounds."
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), based
in South San Francisco, CA, is a development stage company developing proprietary therapeutics with its ProNeura long-term,
continuous drug delivery technology. The ProNeura technology has the potential to be used in developing products for treating a number
of chronic conditions, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical
outcomes. For more information about Titan, please visit www.titanpharm.com.
Forward-Looking Statements
This press release may contain "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.
Such statements include, but are not limited to, any statements relating to our product development programs and any other statements
that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results,
financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations
include those risks and uncertainties relating to our ability to raise capital, the regulatory approval process, the development, testing,
production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships.
We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained
herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is
based, except as required by law.